when to use semaglutide vs Tirzepatide: Head-to-Head for Weight Loss & Diabetes Semaglutide Suppresses Appetite in Grapevine/Southlake,

Liraglutide was the first GLP-1 receptor analogue approved for the management of obesity, thus starting the new era of gastrointestinal peptide agonist pharmacotherapy for the treatment of both diabetes and obesity

doi: 10.3389/fendo.2025.1627909 Received 13 May 2025 Accepted 07 October 2025 Published 23 October 2025 Volume 16 - 2025 Edited by Francesc Xavier Guix, Ramon Llull University, Spain Reviewed by Anu Grover, Mangrove Creations LLP, India Adriyan Pramono, Diponegoro University, Indonesia Updates Copyright 2025 Ghobar, Tarhini, Osman, Sbeih, Ghayda, Matar, Haddad, Kanaan, Eid, Azar, Ghadieh and Harb

To further support the individualisation of glycaemic targets, a patient decision aid has been produced

Non-Stimulant Weight Management Provides a natural approach to fat loss without harsh stimulants, suitable for long-term use